Epidermal-growth-factor-receptor-antagonists/bevacizumab/paclitaxelAcquired drug resistance and lack of efficacy: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2022年 / 1917卷 / 1期

关键词：

D O I：

10.1007/s40278-022-20125-5

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：254 / 254

相关论文

共 50 条

[1] Osimertinib/paclitaxelAcquired drug resistance and lack of efficacy: case report
Reactions Weekly, 2021, 1842 (1) : 292 - 292
[2] Gemcitabine/Osimertinib/PaclitaxelAcquired drug resistance and lack of efficacy: case report
Reactions Weekly, 2024, 2031 (1) : 172 - 172
[3] Epidermal growth factor receptor antagonists/bevacizumab/crizotinibVarious toxicities and drug resistance: 3 case reports
Reactions Weekly, 2020, 1814 (1) : 146 - 146
[4] Antineoplastics/epidermal-growth-factor-receptor-antagonistsCutaneous toxicity, acquired drug resistance and lack of efficacy: case report
Reactions Weekly, 2022, 1907 (1) : 68 - 68
[5] Bevacizumab/Icotinib/OsimertinibAcquired drug-resistance and lack of efficacy: case report
Reactions Weekly, 2024, 2038 (1) : 56 - 56
[6] Antineoplastics/epidermal-growth-factor-receptor-antagonistsLack of efficacy and acquired resistance: case report
Reactions Weekly, 2022, 1926 (1) : 77 - 77
[7] AntibacterialsAcquired drug resistance and lack of efficacy: case report
Reactions Weekly, 2024, 2035 (1) : 48 - 48
[8] AntineoplasticsAcquired drug resistance and lack of efficacy: case report
Reactions Weekly, 2023, 1968 (1) : 37 - 37
[9] AntineoplasticsAcquired drug resistance and lack of efficacy: case report
Reactions Weekly, 2023, 1983 (1) : 51 - 51
[10] AntineoplasticsDevelopment of drug resistance and lack of efficacy: case report
Reactions Weekly, 2023, 1940 (1) : 54 - 54

← 1 2 3 4 5 →